SEC Form SC 13G/A filed by Cerevel Therapeutics Holdings Inc. (Amendment)

5/10/24 10:03:20 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CERE alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.4 CEREVEL THERAPEUTICS HOLDINGS COMMON STOCK Cusip #15678U128 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #15678U128 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 521,647 Item 6: 0 Item 7: 522,877 Item 8: 0 Item 9: 522,877 Item 11: 0.287% Item 12: HC Cusip #15678U128 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 522,877 Item 8: 0 Item 9: 522,877 Item 11: 0.287% Item 12: IN ? Item 1(a). Name of Issuer: CEREVEL THERAPEUTICS HOLDINGS ? Item 1(b). Address of Issuer's Principal Executive Offices:? 222 JACOBS STREET, SUITE 200 CAMBRIDGE, MA 02141 USA ? Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 15678U128 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 522,877 (b) Percent of Class: 0.287% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 522,877 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of CEREVEL THERAPEUTICS HOLDINGS. No one other person's interest in the COMMON STOCK of CEREVEL THERAPEUTICS HOLDINGS is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. ????By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. May 9, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Management & Research Company LLC IA Fidelity Management Trust Company BK Strategic Advisers LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on May 9, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of CEREVEL THERAPEUTICS HOLDINGS at April 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $CERE alert in real time by email

Recent Analyst Ratings for

$CERE

Date	Price Target	Rating	Analyst
12/8/2023	$45.00	Outperform → Market Perform	TD Cowen
11/20/2023	$25.00	Neutral	JP Morgan
9/28/2023	$33.00	Overweight	Piper Sandler
8/3/2023	$36.00 → $31.00	Buy → Neutral	BofA Securities
5/4/2023	$30.00	Equal Weight → Overweight	Wells Fargo
4/10/2023		Outperform	TD Cowen
3/17/2023	$40.00 → $29.00	Overweight → Neutral	JP Morgan
3/16/2023	$22.00	Hold	Berenberg

More analyst ratings

SEC Form SC 13G/A filed by Cerevel Therapeutics Holdings Inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for $CERE

$CERE Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Cerevel Therapeutics downgraded by TD Cowen with a new price target

JP Morgan resumed coverage on Cerevel Therapeutics with a new price target

Piper Sandler initiated coverage on Cerevel Therapeutics with a new price target

$CERE Press Releases

Fastest customizable press release news feed in the world

AbbVie Completes Acquisition of Cerevel Therapeutics

INVESTIGATION ANNOUNCEMENT: BFA Law Announces an Ongoing Investigation into the Merger between Cerevel Therapeutics and AbbVie for Unfair Process

Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease

$CERE SEC Filings

SEC Form 15-12G filed by Cerevel Therapeutics Holdings Inc.

SEC Form EFFECT filed by Cerevel Therapeutics Holdings Inc.

SEC Form EFFECT filed by Cerevel Therapeutics Holdings Inc.

$CERE Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Former 10% Owner Pfizer Inc closing all direct ownership in the company (SEC Form 4)

Director Bain Capital Investors Llc returned 65,679,781 shares to the company (SEC Form 4)

Director Gordon Christopher R returned 65,693,524 shares to the company, closing all direct ownership in the company (SEC Form 4)

$CERE Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Koppel Adam bought $124,999,986 worth of shares (5,480,052 units at $22.81) (SEC Form 4)

Gordon Christopher R bought $124,999,986 worth of shares (5,480,052 units at $22.81) (SEC Form 4)

Bain Capital Investors Llc bought $124,999,986 worth of shares (5,480,052 units at $22.81) (SEC Form 4)

$CERE Market Insights

Live Market Insights

Cerevel Therapeutics shares are trading lower amid unconfirmed rumors of a recommendation memo from FTC staff to challenge the AbbVie merger.

Watching Cerevel Therapeutics; Traders Circulating M&A Blog Comments Saying A Recommendation Memo From The Staff At The FTC To "Challenge" The CERE/ABBV Merger Is Being Considered

U.S. FTC Sues To Block Tempur Sealy's Purchase Of Mattress Firm, Agency Says

$CERE Leadership Updates

Live Leadership Updates

Cerevel Therapeutics Appoints Paul Burgess as Chief Business Development and Strategic Operations Officer

Cerevel Therapeutics Appoints Susan Altschuller, Ph.D. as Chief Financial Officer

Cerevel Therapeutics Announces the Appointment of Scott M. Akamine as Chief Legal Officer

$CERE Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Cerevel Therapeutics Holdings Inc.

Amendment: SEC Form SC 13D/A filed by Cerevel Therapeutics Holdings Inc.

SEC Form SC 13G/A filed by Cerevel Therapeutics Holdings Inc. (Amendment)

$CERE Financials

Live finance-specific insights

AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline

Cerevel Therapeutics to Report Third Quarter 2023 Financial Results and Business Updates on Wednesday, November 1, 2023

Cerevel Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

Recent Analyst Ratings for
$CERE

$CERE
Analyst Ratings

$CERE
Press Releases

$CERE
SEC Filings

$CERE
Insider Trading

$CERE
Insider Purchases

$CERE
Market Insights

$CERE
Leadership Updates

$CERE
Large Ownership Changes

$CERE
Financials